Last reviewed · How we verify
Stimulants
Stimulants is a Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 2 development.
Stimulants are a class of psychoactive drugs that increase alertness and are used for various purposes, such as enhancing attention, motivation, cognition, mood, and physical performance. Lisdexamfetamine, a partial agonist of the beta-1 adrenergic receptor, is a type of stimulant used to treat conditions including bipolar depression, attention deficit disorder with hyperactivity, and prescription drug abuse.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Eli Lilly and Company is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Stimulants |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Substance Misuse To Psychosis for Stimulants (PHASE2, PHASE3)
- Dronabinol in Total Knee Arthroplasty (TKA) (PHASE4)
- Kentucky Women's Justice Community Overdose Innovation Network - Phase II (NA)
- Developing and Testing Innovative Care Pathways for Screening and Treatment of OUD/PTSD in Jails (NA)
- Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol (PHASE3)
- Health Outcomes by Neighborhood - Baltimore
- tTIS Targeted of the Striatum as an Intervention for MUD Patients (NA)
- LDART for Stimulant Use Disorder (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stimulants CI brief — competitive landscape report
- Stimulants updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Stimulants
What is Stimulants?
Who makes Stimulants?
What development phase is Stimulants in?
Related
- Manufacturer: Eli Lilly and Company — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing